These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6223427)

  • 21. Dysfunctional plasminogen in full term newborn--study of active site of plasmin.
    Benavent A; Estellés A; Aznar J; Martinez-Sales V; Gilabert J; Fornas E
    Thromb Haemost; 1984 Feb; 51(1):67-70. PubMed ID: 6232730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Separation of plasmin and plasminogen-activator from SK-activatable fraction B of human plasma (author's transl)].
    Yamamoto J
    Nihon Ketsueki Gakkai Zasshi; 1974 Apr; 37(2):107-20. PubMed ID: 4277925
    [No Abstract]   [Full Text] [Related]  

  • 24. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation in assays of standard SK and plasmin preparations: evidence for and effect of variability of plasmins, plasminogen, and fibrinogen.
    Johnson AJ; Tse A; Skoza L
    Fed Proc; 1966; 25(1):34-41. PubMed ID: 4283648
    [No Abstract]   [Full Text] [Related]  

  • 26. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain.
    Boivin D; Provençal M; Gendron S; Ratel D; Demeule M; Gingras D; Béliveau R
    Arch Biochem Biophys; 2004 Nov; 431(2):197-206. PubMed ID: 15488468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal plasminogen Maywood I.
    Robbins KC; Boreisha IG; Godwin JE
    Thromb Haemost; 1991 Nov; 66(5):575-80. PubMed ID: 1803622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation of a novel streptokinase mutant with improved stability.
    Shi GY; Chang BI; Su SW; Young KC; Wu DH; Chang LC; Tsai YS; Wu HL
    Thromb Haemost; 1998 May; 79(5):992-7. PubMed ID: 9609235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis.
    Smith RA; Dupe RJ; English PD; Green J
    Thromb Haemost; 1982 Jun; 47(3):269-74. PubMed ID: 6214039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of endogenous fibrinolysis activation on human plasminogen].
    Platonova TK; Kalashnikov VV; Khvatov VB
    Biull Eksp Biol Med; 1987 Jan; 103(1):59-61. PubMed ID: 2432967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The isolation and characterization of the S-carboxymethyl beta (light) chain derivative of human plasmin. The localization of the active site on the beta (light) chain.
    Summaria L; Hsieh B; Groskopf WR; Robbins KC
    J Biol Chem; 1967 Nov; 242(21):5046-52. PubMed ID: 4228673
    [No Abstract]   [Full Text] [Related]  

  • 33. Kinetic properties of the activator complexes plasmin--staphylokinase and plasmin(ogen)--streptokinase in vitro.
    Sazonova IY; Aisina RB; Muhametova LI; Varfolomeyev SD
    Biochemistry (Mosc); 1999 Jan; 64(1):66-74. PubMed ID: 9986915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homocysteine and its thiolactone impair plasmin activity induced by urokinase or streptokinase in vitro.
    Kolodziejczyk-Czepas J; Talar B; Nowak P; Olas B; Wachowicz B
    Int J Biol Macromol; 2012 Apr; 50(3):754-8. PubMed ID: 22197896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the reliability of plasminogen measurement employing the proactivator-activator converting method.
    Martin M
    Thromb Haemost; 1976 Dec; 36(3):551-65. PubMed ID: 138961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower molecular weight species of alpha 2-macroglobulin-plasmin complexes in human plasma activated by urokinase.
    Yamamoto J; Okamoto U
    Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):1090-9. PubMed ID: 2414954
    [No Abstract]   [Full Text] [Related]  

  • 37. Multiple exosites distributed across the three domains of streptokinase co-operate to generate high catalytic rates in the streptokinase-plasmin activator complex.
    Aneja R; Datt M; Yadav S; Sahni G
    Biochemistry; 2013 Dec; 52(49):8957-68. PubMed ID: 23919427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Characterization of various streptokinase dosage schedules through quantitative streptokinase, plasminogen and plasmin determinations in the plasma of patients].
    Büchner U; Martin M; Auel H
    Verh Dtsch Ges Inn Med; 1975; 81():1152-5. PubMed ID: 132799
    [No Abstract]   [Full Text] [Related]  

  • 39. Interaction of streptokinase and human plasminogen. 3. Plasmin and activator activities in reaction mixtures of streptokinase and human plasminogen or human plasmin of various molar ratios.
    Hummel BC; Buck FF; De Renzo EC
    J Biol Chem; 1966 Aug; 241(15):3474-9. PubMed ID: 4224092
    [No Abstract]   [Full Text] [Related]  

  • 40. Fibrinolytic treatment by infusion of streptokinase-plasminogen-complex (activator): laboratory effects.
    Martin H; Auel H; Riedel C
    Behring Inst Mitt; 1986 Feb; (79):263-71. PubMed ID: 2424424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.